NicOx starts Phase II NO-aspirin trial

NicOx (NM:Nicox) began a Swiss Phase II trial of its NCX 4016 nitric oxide-releasing aspirin derivative to treat insulin resistance. The trial will assess improvements in insulin sensitivity and relev...